Chronic myeloid leukemia: Global impact from a local laboratory. - Suppr | 超能文献

Chronic myeloid leukemia: Global impact from a local laboratory.

作者信息

Radich Jerald P

机构信息

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

出版信息

Cancer. 2017 Jul 15;123(14):2594-2596. doi: 10.1002/cncr.30776. Epub 2017 Jun 6.

DOI:10.1002/cncr.30776

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Chronic myeloid leukemia: Global impact from a local laboratory.

Cancer. 2017 Jul 15;123(14):2594-2596. doi: 10.1002/cncr.30776. Epub 2017 Jun 6.

2

Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.慢性髓性白血病中BCR-ABL1激酶结构域突变的反射性筛查

Clin Lab. 2016;62(5):975-6. doi: 10.7754/clin.lab.2015.150938.

3

Impact of assay procedures on detection of MR status in chronic myeloid leukemia: Optimization of cDNA synthesis.

Int J Lab Hematol. 2019 Oct;41(5):e109-e112. doi: 10.1111/ijlh.13004. Epub 2019 Mar 12.

4

Chronic myelogenous leukemia. Preface.慢性粒细胞白血病。前言。

Hematol Oncol Clin North Am. 2011 Oct;25(5):ix-x. doi: 10.1016/j.hoc.2011.10.001.

5

Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.为什么酪氨酸激酶抑制剂无法治愈慢性髓性白血病。

Leukemia. 2021 Aug;35(8):2199-2204. doi: 10.1038/s41375-021-01272-8. Epub 2021 May 17.

6

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.仅比较体外细胞数据不足以预测临床反应并指导用于治疗伊马替尼耐药慢性髓性白血病的BCR-ABL抑制剂的选择。

J Clin Oncol. 2010 Apr 10;28(11):e169-71; author reply e172. doi: 10.1200/JCO.2009.26.4945. Epub 2010 Mar 1.

7

BCR-ABL1 mutation screening in chronic myeloid leukaemia: is next now?慢性髓性白血病中的BCR-ABL1突变筛查：下一个会是现在吗？

Lancet Haematol. 2019 May;6(5):e236-e237. doi: 10.1016/S2352-3026(19)30046-8.

8

Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.BCR-ABL TKIs 耐药机制及治疗策略：综述。

Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13.

9

[Drug development and future scope to BCR-ABL inhibitor for chronic myeloid leukemia].[慢性髓性白血病的BCR-ABL抑制剂的药物研发及未来前景]

Gan To Kagaku Ryoho. 2011 May;38(5):754-8.

10

Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.

Leuk Lymphoma. 2024 Jul;65(7):1024-1027. doi: 10.1080/10428194.2024.2331625. Epub 2024 Mar 21.

引用本文的文献

1

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance.慢性髓性白血病中对酪氨酸激酶抑制剂的耐药性——从分子机制到临床相关性

Cancers (Basel). 2021 Sep 26;13(19):4820. doi: 10.3390/cancers13194820.

2

Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.探究慢性骨髓增殖性恶性肿瘤的分子遗传学以用于2021年的个性化管理。

Haematologica. 2021 Jul 1;106(7):1787-1793. doi: 10.3324/haematol.2020.267252.